Lab

János G Filep's Lab


Featured research (3)

Neutrophils act as the first line of cellular defense against invading pathogens or tissue injury. Their rapid recruitment into inflamed tissues is critical for the elimination of invading microorganisms and tissue repair, but is also capable of inflicting damage to neighboring tissues. The β2 integrins and Mac-1 (CD11b/CD18, αMβ2 or complement receptor 3) in particular, are best known for mediating neutrophil adhesion and transmigration across the endothelium and phagocytosis of microbes. However, Mac-1 has a broad ligand recognition property that contributes to the functional versatility of the neutrophil population far beyond their antimicrobial function. Accumulating evidence over the past decade has demonstrated roles for Mac-1 ligands in regulating reverse neutrophil transmigration, lifespan, phagocytosis-induced cell death, release of neutrophil extracellular traps and efferocytosis, hence extending the traditional β2 integrin repertoire in shaping innate and adaptive immune responses. Understanding the functions of β2 integrins may partly explain neutrophil heterogeneity and may be instrumental to develop novel therapies specifically targeting Mac-1-mediated pro-resolution actions without compromising immunity. Thus, this review details novel insights on outside-in signaling through β2 integrins and neutrophil functional heterogeneity pertinent to the resolution of inflammation.
Neutrophil granulocytes form the first line of host defense against invading pathogens and tissue injury. They are rapidly recruited from the blood to the affected sites, where they deploy an impressive arsenal of effectors to eliminate invading microbes and damaged cells. This capacity is endowed in part by readily mobilizable proteins acquired during granulopoiesis and stored in multiple types of cytosolic granules with each granule type containing a unique cargo. Once released, granule proteins contribute to killing bacteria within the phagosome or the extracellular milieu, but are also capable of inflicting collateral tissue damage. Neutrophil‐driven inflammation underlies many common diseases. Research over the last decade has documented neutrophil heterogeneity and functional versatility far beyond their antimicrobial function. Emerging evidence indicates that neutrophils utilize granule proteins to interact with innate and adaptive immune cells and orchestrate the inflammatory response. Granule proteins have been identified as important modulators of neutrophil trafficking, reverse transendothelial migration, phagocytosis, neutrophil life span, neutrophil extracellular trap formation, efferocytosis, cytokine activity, and autoimmunity. Hence, defining their roles within the inflammatory locus is critical for minimizing damage to the neighboring tissue and return to homeostasis. Here, we provide an overview of recent advances in the regulation of degranulation, granule protein functions, and signaling in modulating neutrophil‐mediated immunity. We also discuss how targeting granule proteins and/or signaling could be harnessed for therapeutic benefits.
Significance Timely resolution of bacterial infections critically depends on phagocytosis of invading pathogens by polymorphonuclear neutrophil granulocytes, followed by neutrophil apoptosis and removal by macrophages. Neutrophils integrate cues from the inflammatory microenvironment. Here we show a Toll-like receptor 9-mediated mechanism, involving regulation of phagocytosis and phagocytosis-induced neutrophil apoptosis, by which bacterial DNA, a pathogen-associated molecular pattern, and the danger signal mitochondrial DNA may impair host defense to bacteria and prolong the inflammatory response. We also report that the proresolution aspirin-triggered lipids 15-epi-lipoxin A 4 and 17-epi-resolvin D1 restore impaired phagocytosis and enhance bacterial clearance and phagocytosis-induced neutrophil apoptosis, thereby facilitating resolution of acute lung inflammation. These findings imply the lipoxin receptor ALX/FPR2 as a potential therapeutic target for combating bacterial infections.

Lab head

Members (3)

Driss El Kebir
  • Hôpital Maisonneuve-Rosemont
Salma A Rizo Tellez
  • Université de Montréal
Meriem Sekheri
  • Université de Montréal
János G. Filep
János G. Filep
  • Not confirmed yet
Meriem Shekeri
Meriem Shekeri
  • Not confirmed yet
Everton de Oliveira Lima dos Santos
Everton de Oliveira Lima dos Santos
  • Not confirmed yet